Binding in vivo of selective mu and delta opioid receptor agonists: opioid receptor occupancy by endogenous enkephalins.
The in vivo binding properties of cerebral mu and delta opioid receptors were investigated in mice after the intrastriatal injection of [3H][D-Ala2, MePhe4, Gly-ol5]enkephalin (DAGO) or [3H][D-Thr2,Leu5]enkephalyl-Thr (DTLET). Both peptides exhibited similar diffusion kinetics in the brain and 30-40% of [3H]DAGO or [3H]DTLET was shown to be present in the tissue 15 min after injection when maximal binding was observed. The specific binding of both agonists, defined as the fraction of the radioactivity bound to brain membranes which was displaced by 10 nmol of cold ligand, was reversible, saturable and displayed a pharmacological profile similar to that found in in vitro experiments. At doses producing a similar analgesic effect in the hot-plate test in mice, DTLET occupied 64% of delta sites and DAGO 15% of mu sites. However, because of the residual cross-reactivity of DTLET for mu sites, it appeared that both ligands occupied a similar number of mu receptors at their ED50 values, thus supporting a preferential involvement of mu opioid binding sites in the supraspinal pain control. [Met5]enkephalin inhibited the in vivo binding of both agonists only when the peptide was protected from degradation by the co-administration of a mixed inhibitor of enkephalin degrading enzymes RB38A (N[3(R)(hydroxyaminocarbonyl)-2-benzyl-1-oxopropyl]- L-phenylalanine). Unlike thiorphan, 5 nmol RB38A alone was able to inhibit [3H]DAGO binding by 60%. This result is the first direct demonstration of the existence of an in vivo tonic control of mu opioid receptor occupation by endogenous opioid peptides.
Meucci
E
E
Département de Chimie Organique, U 266 INSERM, Paris, France.
Delay-Goyet
P
P
Roques
B P
BP
Zajac
J M
JM
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D003342:Corpus Striatum; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004745:Enkephalins / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology; D006877:Hydroxamic Acids / Q000378:metabolism; D066298:In Vitro Techniques; D007267:Injections; D007700:Kinetics; D008297:Male; D051379:Mice; D009020:Morphine / Q000494:pharmacology; D009842:Oligopeptides / Q000009:adverse effects / Q000378:metabolism; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism*; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D015244:Thiorphan / Q000494:pharmacology
D004745:Enkephalins; D006877:Hydroxamic Acids; D009842:Oligopeptides; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; C061042:3-(N-hydroxycarboxamido-2-benzylpropanoyl)phenylalanine; D010649:Phenylalanine; D009020:Morphine; C037653:deltakephalin; D015244:Thiorphan